文献速递核素与放射性配体治疗肿瘤 PET/CT

弥合成纤维激活蛋白靶向放射性核素治疗差距:转化视角

Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-02-02

本文综述了FAP靶向放射性核素治疗(FAP-TRT)的转化进展与挑战,指出临床转化受限于疗效中等、肿瘤滞留时间短和反应高度异质。文章强调需关注CAF异质性、亚致死照射的潜在促瘤效应及旁观者/远隔效应不确定性,并建议优化剂量学、开发生物标志物、完善患者选择及联合免疫检查点抑制剂。

要点

  • FAP-TRT通过清除FAP表达CAF调节肿瘤微环境,临床疗效有限且异质。
  • 需关注CAF异质性、亚致死照射促瘤效应及旁观者/远隔效应不确定性。
  • 未来方向包括优化剂量学、预测生物标志物、患者选择及联合ICI。

核心结论

  • FAP-TRT临床转化受限于疗效中等、肿瘤滞留短和反应异质,需多维度优化弥合差距。

研究设计与样本

  • 综述总结FAP-TRT放射药物设计进展、早期临床发现和正在进行试验,并讨论转化挑战。

主要发现

  • 临床前研究在多种肿瘤模型中显示有前景结果,但临床转化仍受限。
  • CAF异质性、亚致死照射促瘤效应及旁观者/远隔效应贡献不确定影响疗效。

临床怎么用

  • 需开发转化相关肿瘤模型、优化剂量学、预测生物标志物和细化患者选择标准。
  • 可考虑联合免疫检查点抑制剂(ICI)作为未来方向。

局限性

  • 临床转化受限于疗效中等、肿瘤滞留短和反应异质,早期临床证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein-targeted radionuclide therapy (FAP-TRT) has emerged as a novel strategy for modulating the tumour microenvironment (TME) by selectively eradicating FAP-expressing cancer-associated fibroblasts (CAFs). Although preclinical studies have demonstrated promising results across various tumour models using diverse radiolabelled FAP inhibitors, clinical translation remains limited by modest efficacy, short tumour retention, and highly heterogeneous responses. This review aims to provide an overview of recent advances in radiopharmaceutical design to enhance tumour targeting and prolong retention. Furthermore, we summarise early clinical findings and ongoing trials, while emphasising the potential translational challenges of FAP-TRT. Special emphasis is placed on the radiobiological underpinnings of FAP-TRT, including the impact of CAFs heterogeneity, potential pro-tumorigenic effects of sublethal irradiation, and the uncertain contribution of bystander and abscopal effects. We further highlight the need for the development of translationally relevant tumour models, optimised dosimetry, predictive biomarkers, and refined patient selection criteria. Finally, we propose future directions such as combination therapy with immune checkpoint inhibitors (ICIs). Together, these insights aim to bridge the gap between promising preclinical efficacy and limited clinical outcomes in FAP-TRT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wu C, Kurniawan A, Ming Z, et al. Bridging the gaps in fibroblast activation protein targeted radionuclide therapy: a translational perspective. Eur J Nucl Med Mol Imaging. 2026. PMID: 41622307. doi:10.1007/s00259-025-07711-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。